谁会更快：强生葛兰素史克拟合力开发埃博拉疫苗

道路漫长黑暗

    由于埃博拉感染者的死亡率被认为上升至70%，使用未经过充分临床试验的药物治疗埃博拉感染者已获得WHO认可，突破这一伦理学障碍后，美国马普公司的Zmapp大放光彩，包括英国护士在内的感染者均获得Zmapp治疗。但据说本品生产工艺复杂产量有限，现存Zmapp已不可获得，利比里亚政府向美国政府申请获批后也仅获得12剂，可以认为目前埃博拉感染者不会获得明确有效的药物治疗。与此同时制药巨头强生与葛兰素史克已做好准备合作开发埃博拉疫苗，葛兰素史克乐观估计年底前可完成埃博拉疫苗。

     Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

J&J, which aims to have at least 1 million doses of its two-step vaccine available next year, said on Wednesday that vaccine makers would work together to maximise production of which ever vaccine proved successful in clinical trials.

Paul Stoffels, head of research at J&J, told reporters it was also possible that rival vaccines being developed by J&J and GSK could potentially be combined, if that looked like the most promising approach. (Reporting by Ben Hirschler, editing by Louise Heavens)

七-月

无论谁快都是好的……